Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Cardiol Therapeutics
(NQ:
CRDL
)
1.930
-0.070 (-3.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
157,821
Open
2.010
Bid (Size)
1.930 (6)
Ask (Size)
2.110 (4)
Prev. Close
2.000
Today's Range
1.930 - 2.010
52wk Range
0.6610 - 3.120
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024
August 12, 2024
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
June 17, 2024
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II...
Via
TheNewswire.com
Exposures
Product Safety
Performance
YTD
+119.32%
+119.32%
1 Month
-14.22%
-14.22%
3 Month
-17.70%
-17.70%
6 Month
+12.21%
+12.21%
1 Year
+99.50%
+99.50%
More News
Read More
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
June 17, 2024
Via
News Direct
Exposures
Product Safety
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
June 13, 2024
Via
Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
Via
AB Newswire
Topics
ETFs
Exposures
Product Safety
Stocks That Hit 52-Week Lows On Wednesday
October 19, 2022
Via
Benzinga
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
Via
TheNewswire.com
Topics
ETFs
Exposures
Product Safety
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
May 28, 2024
Via
AB Newswire
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
May 28, 2024
Via
News Direct
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
May 14, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023
April 02, 2024
Via
InvestorPlace
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
February 21, 2024
Via
Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
February 15, 2024
Via
Newsfile
Exposures
Product Safety
Cardiol Therapeutics - This Penny Stock Is An Analysts Favorite
January 31, 2024
Via
Talk Markets
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
November 01, 2023
Via
Newsfile
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Via
Get News
Topics
Death
Exposures
Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Via
News Direct
Topics
Death
Exposures
Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Via
TheNewswire.com
Topics
Death
Exposures
Death
Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations
October 12, 2023
Via
Benzinga
CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects
October 10, 2023
Via
Benzinga
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
October 10, 2023
Via
Newsfile
Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
September 21, 2023
Via
Benzinga
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
September 19, 2023
Via
Newsfile
Sidoti's Micro-Cap Virtual May Conference
May 09, 2023
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.